TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range
The clinical-stage biotech sold about 8.3 million shares at $14 each, the low end of its $14-to-$16 marketed range
We haven't written up this one. Quartz has the full story — the link below goes straight to it.